Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA:688192)

SHA:688192 Revenue

Dizal (Jiangsu) Pharmaceutical had revenue of 252.52M CNY in the quarter ending March 31, 2026, with 58.18% growth. This brings the company's revenue in the last twelve months to 894.02M, up 104.01% year-over-year. In the year 2025, Dizal (Jiangsu) Pharmaceutical had annual revenue of 801.14M with 122.60% growth.

• Revenue (ttm): 894.02M
• Revenue Growth: +104.01%
• P/S Ratio: 29.95
• Revenue / Employee: 886.04K
• Employees: 1,009
• Market Cap: 26.77B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	801.14M	441.23M	122.60%
Dec 31, 2024	359.90M	268.61M	294.24%
Dec 31, 2023	91.29M	-	-
Dec 31, 2022	-	-	-
Dec 31, 2021	10.29M	-17.48M	-62.95%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

May 16, 2026

Data Sources Report a data error